Results 141 to 150 of about 6,066,484 (285)

D. Seifried, N. Stark: Energiedienstleistungen

Technikfolgenabschätzung – Theorie und Praxis, 1994
TATuP editorial office
doaj   +1 more source

ÐеÑекÑÑÑ ÑÑÑка Ñ Ð½Ð¾Ð²Ð¾Ð½Ð°ÑÐ¾Ð´Ð¶ÐµÐ½Ð¸Ñ Ð´ÑÑей

, 2015
P. S. Rusak
openalex   +2 more sources

ИÑпитување на концентрациониот механизам за пертехнетат во тиреоидеата, плунчаните жлезди и желудникот кај Ñтаорец

, 2016
The pertechnetate concentrating mechanism in thyroid gland, salivary glands and stomach was studied in rats by determination tissue: plasma radioactivity ratio.
Радуловиќ (Radulovikj), ВеÑна (Vesna), Серафимов (Serafimov), Ðикола (Nikola), Ðнгелова (Angelova), Г (G)   +2 more
core  

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

ÐлÑнÑко-ÑеÑнологÑÑÐ½Ñ Ð²Ð»Ð°ÑÑивоÑÑÑ Ð¾ÑÐ½Ð¾Ð²Ð½Ð¸Ñ Ð¼Ð°ÑеÑÑалÑв, ÑÐºÑ Ð²Ð¸ÐºÐ¾ÑиÑÑовÑÑÑÑÑÑ Ð² оÑÑопедиÑнÑй ÑÑомаÑологÑÑ

, 2014
Д. Д. Кіндій, В. Д. Кіндій, М. М. Малюченко   +2 more
openalex   +2 more sources

ПолициÑтична бубрежна болеÑÑ‚ - приказ на пациент

, 2016
Was to present disease, over a patient review of policystic kidney disease, that need hospitalization many times – because of complications that follow it (uroinfection, calculosis, anaemia, chronical kidney insufficiency, hypertension, and cistes crack ...
Поленаковиќ (Polenakovikj), Момир (Momir), Миленковиќ (Milenkovikj), Звонко (Zvonko)   +1 more
core  

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Ð¢ÐµÑ Ð½Ð¾Ð»Ð¾Ð³Ð¸Ñ Ð¸Ð·Ð³Ð¾ÑÐ¾Ð²Ð»ÐµÐ½Ð¸Ñ Ñзла ÑÑдового Ð¼ÐµÑ Ð°Ð½Ð¸Ð·Ð¼Ð° по наÑÑÑÐ½Ð¾Ð¼Ñ Ð¾Ð±ÑазÑÑ Ð² ÑÑловиÑÑ ÑемонÑа

, 2016
Николай Николаевич Сучков
openalex   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

ÐÑенка ÑÑÑекÑивноÑÑи внедÑÐµÐ½Ð¸Ñ ÐÐШ на плаÑÑоÑме SAP-HR на пÑимеÑе гÑÑÐ¿Ð¿Ñ ÐºÐ¾Ð¼Ð¿Ð°Ð½Ð¸Ð¹ «ÐÐ-Рл

, 2016
Анастасия Олеговна Зубова
openalex   +1 more source